Drugs / SKB103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07459998 | Apr 2026 → Dec 2029 expected | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Regulatory Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC kelun-biotech.com ↗
The approval marks SKB103 as the Company's first TAA-PD-L1 bsADC candidate and its second bsADC program for tumor therapy to enter the clinical stage, following SKB571. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC kelun-biotech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKB103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07459998 ↗ |
| Route | Intravenous | “IV infusion on Day 1 of each cycle” NCT07459998 ↗ |